ENGEL JURGEN
No ORCID on file
· 26 papers in corpus
· active 2004-2006
Frequent coauthors
- BAUER HORST 13
- DIEDRICH KLAUS 13
- DAMM MICHAEL 13
- FELBERBAUM RICARDO 13
- KUPKER WOLFGANG 13
- RIETHMULLER-WINZEN HILDE 13
- STACH GABRIELE 13
- SALONEK WALDEMAR 13
2006
The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to …
2006
The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to …
2006
The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to …
2006
The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to …
2006
The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to …
2006
The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to …
2006
The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to …
2006
The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to …
2006
The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to …
2006
The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to …
2006
The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to …
2006
The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to …
2006
The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to …
2004
A composition comprising a peptide salt having a pharmaceutically acceptable anion prepared by the method comprising the steps of: contacting a first peptide salt with a diluent to form a diluent solution; contacting the diluent solution co…
2004
A composition comprising a peptide salt having a pharmaceutically acceptable anion prepared by the method comprising the steps of: contacting a first peptide salt with a diluent to form a diluent solution; contacting the diluent solution co…
2004
A composition comprising a peptide salt having a pharmaceutically acceptable anion prepared by the method comprising the steps of: contacting a first peptide salt with a diluent to form a diluent solution; contacting the diluent solution co…
2004
A composition comprising a peptide salt having a pharmaceutically acceptable anion prepared by the method comprising the steps of: contacting a first peptide salt with a diluent to form a diluent solution; contacting the diluent solution co…
2004
A composition comprising a peptide salt having a pharmaceutically acceptable anion prepared by the method comprising the steps of: contacting a first peptide salt with a diluent to form a diluent solution; contacting the diluent solution co…
2004
A composition comprising a peptide salt having a pharmaceutically acceptable anion prepared by the method comprising the steps of: contacting a first peptide salt with a diluent to form a diluent solution; contacting the diluent solution co…
2004
A composition comprising a peptide salt having a pharmaceutically acceptable anion prepared by the method comprising the steps of: contacting a first peptide salt with a diluent to form a diluent solution; contacting the diluent solution co…
2004
A composition comprising a peptide salt having a pharmaceutically acceptable anion prepared by the method comprising the steps of: contacting a first peptide salt with a diluent to form a diluent solution; contacting the diluent solution co…
2004
A composition comprising a peptide salt having a pharmaceutically acceptable anion prepared by the method comprising the steps of: contacting a first peptide salt with a diluent to form a diluent solution; contacting the diluent solution co…
2004
A composition comprising a peptide salt having a pharmaceutically acceptable anion prepared by the method comprising the steps of: contacting a first peptide salt with a diluent to form a diluent solution; contacting the diluent solution co…
2004
A composition comprising a peptide salt having a pharmaceutically acceptable anion prepared by the method comprising the steps of: contacting a first peptide salt with a diluent to form a diluent solution; contacting the diluent solution co…
2004
A composition comprising a peptide salt having a pharmaceutically acceptable anion prepared by the method comprising the steps of: contacting a first peptide salt with a diluent to form a diluent solution; contacting the diluent solution co…